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Abstract: 
Protein kinases are important drug targets in human cancers, inflammation and metabolic diseases. Docking studies was 
performed for all the benzimidazopyrimidine and coumarin substituted benzimidazopyridimine derivatives with human Aurora A 
kinase target (3FDN) employing flexible ligand docking approach by using AutoDock 4.2. All the compounds were found to have 
minimum binding energy ranging from -6.26 to -9.29 kJ/mol. Among the molecules tested for docking study, 10-(6-Bromo-2-oxo-
2H-chromen-4-ylmethyl)-2-isopropyl-10H-benzo[4,5]imidazo[1,2-a]pyrimidin-4-one (2k) showed minimum binding energy (-9.29 
kJ/mol) with  ligand efficiency of -0.31. All the ligands were docked deeply within the binding pocket region of 3FDN showing 
hydrogen bonds with Ala 213 and Asn 261. The docking study results showed that these derivatives are excellent inhibitor of 
human Aurora A kinase target; and also all these docked compounds have good inhibition constant, vdW + Hbond + desolv 
energy with best RMSD value. 
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Background: 
Benzimidazopyrimidine belonging to the fused heterocyclic 
system have three nitrogen atoms.  The most prominent 
benzimidazole moiety in nature is N-ribosyl -dimethyl 
benzimidazole, which serves as an axial ligand for cobalt in 
vitamin B12 [1]. Literature survey revealed that benzimidazole 
derivatives play a vital role in biological activities such as 
antifungal, kinase inhibitor, anti-hepatitis-C-virus, 
antidepressant and anticancer [2-8]. Also, heterocycles 
containing an imidazolone moiety exhibits various biological 
activities such as antibacterial and antifungal activities [9-11]. 
Coumarins are an important class of widely distributed 
heterocyclic natural products exhibiting several biological 
properties. 4-Amino-3-(2-methylbenzyl)coumarin derivatives 
[12] exhibited potent estrogenic activity on the estrogen 
receptor positive (ER+) human MCF-7 breast cancer cell line. 
Benzothiazolyl coumarin acetamide derivatives [13] exhibited 
strong in vitro anti-HIV effect against the wild-type HIV-1 cell 
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line. The in vitro antioxidant activities of 4-schiff bases-7-
benzyloxy coumarin derivatives [14] revealed that DPPH and 
ABTS+ radical scavenging activities were better than that of the 
commercial antioxidant BHT. 
 
Human protein kinases are attractive targets for the 
development of new therapeutics because of their involvement 
in processes associated with the progression of cancers and 
metabolic diseases [15, 16]. Aurora kinase family of 
serine/threonine kinase regulates some important events 
during mitosis. They play key roles in centrosome maturation 
and separation, mitotic spindle assembly and chromosome 
segregation [17]. The Aurora kinase A is commonly 
overexpressed in many tumor cell lines and human primary 
tumours [18]. In addition, Aurora A has the ability to transport 
cell lines that are capable of forming tumours in mice [19]. The 
role of Aurora A in the cell cycle and tumorogenesis suggested 
that the inhibition of the kinase activity have remarkable value 
for the development of small molecular therapeutics for cancer 
treatment. Based on the current success of Aurora kinase 
inhibitors in the development of kinase-based cancer therapy, 
we have initiated a virtual screening program for the 
identification of Aurora kinase inhibitors. 
 
In our previous paper [20], we have reported the synthesis, in 
vitro antimicrobial and anticancer activities of novel coumarin 
substituted dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-4-ones. 
In continuation to this, we study herewith, the crystal structure 
(2g) and molecular docking studies of benzimidazopyrimidine 
and coumarin substituted benzimidazopyridimine derivatives 
with human Aurora A kinase target to evaluate their potential 
value for the treatment of cancers. 
 
 
Figure 1: Structure of (A) Bennzimidazopyrimidine (B) 
Coumarin substituted benzimidazopyridimine derivatives. 
 
Methodology: 
Preparation of ligands 
The 2D structures (.mol) of all the thirteen compounds as 
tabulated in Table 1 (see supplementary material) were drawn 
and the structure was analyzed by using ChemDraw Ultra 12.0. 
All the compounds (2a-2k) are converted to 3D structure (.pdb) 
using Openbable software tool. The 3D coordinates (.pdb) of 
each molecule were loaded on to Dundee PRODRG server for 
energy minimization [21]. The structure of the 
benzimidazopyridimine and coumarin substituted 
benzimidazopyridimines are shown in Figure 1. 
 
Preparation of macromolecule 
The protein target, which is retrieved from the RCSB Protein 
Data Bank (PDB code 3FDN) serves as docking receptor [22]. 
All the bound ligands and water molecules were removed from 
the active site of the receptor. For docking target, crucial amino 
acids of the active site were identified using data in pdbsum as 
shown in Figure 2 [23]. 
 
X-ray structure determination 
A single crystal of the compound (2g) with dimensions of 0.30 × 
0.25 × 0.20 mm was chosen for X-ray diffraction studies. The 
data were collected on a Bruker SMART APEX II X-ray 
diffractometer with graphite monochromated MoKα radiation, 
operating at 50 kV and 30 mA. Raw data was processed and 
reduced by using APEX2 and SAINT [24]. The structure was 
solved by direct methods using SHELXS-97 [25]. All non-
hydrogen atoms were revealed in the first Fourier map itself. 
Full-matrix least squares refinement was carried out using 
SHELXL-97 [25]. Anisotropic refinement of non-hydrogen 
atoms was started at this stage. Subsequent refinements were 
carried out with anisotropic thermal parameters for non-
hydrogen atoms and isotropic temperature factors for the 
hydrogen atoms which were placed at chemically acceptable 
positions. CCDC- 990917 contains the supplementary 
crystallographic data of molecule 2g [26]. The X-ray structure of 
this compound (2g) was used for the docking studies. 
 
 
Figure 2: Ligplot results of Aurora A (3FDN), showing the 
binding of ligand Mmh 1(A) with amino acid residues present 
in an active site pocket. 
 
Molecular docking 
The molecular docking was performed and analyzed using 
AutoDock 4.2. A Lamarkian genetic algorithm method 
implemented in the program suite was employed to identify 
appropriate binding modes and conformation of the ligand 
molecules. Gasteiger charges were added and the rotatable 
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bonds were set by the AutoDock tools and all torsions were 
allowed to rotate. Polar hydrogen atoms were added and 
Kollaman charges were assigned to the protein using AutoDock 
tools (ADT). The grid map was centered at the active site 
pocket of the protein by Autogrid. The grid map which was 
centered at the following residues of the protein (Thr 217, Arg 
220, Arg 137, Leu 139, Pro 214, Ala 213, Gly 216, Tyr 212, Gly 
140, Leu 263, Val 147, Glu 211, Leu 194, Leu 210, Ala 160) were 
predicted from the ligplot (Figure 2). In all the cases, we have 
used grid maps with a grid box size of 55×55×55 Ǻ3 points with 
a grid-point spacing of 0.375 Ǻ. During docking, centre grid 
parameters were specified for x, y and z axis as -2.0, -32.0 and 
7.0, respectively. The Lamarckian genetic algorithm, the 
pseudo-Solis and Wets methods were applied for minimization 
using default parameters. Binding energy, torsional energy, 
intermolecular energy, number of H-bonds and RMS value 
were recorded in each ligand bound conformations. The details 
of dock score results of the different benzimidazopyrimidine 
derivatives are given in Table 2 (see supplementary material). 
 
 
Figure 3: Enfolding of molecules 2e, 2f, 2h and 2k in the active 
site pocket 
 
Results & Discussion: 
The crystal structure analysis showed that the compound (2g) 
crystallizes in monoclinic system under the space group P21/n 
with cell parameters, a = 9.3819(12) Å, b = 8.0471(10) Å, c = 
26.808(4) Å, β = 93.592(7)º and Z=4. The crystal structure was 
solved by direct methods and refined by full-matrix least 
squares on F2 to a final residual value of R1 = 0.0486. 
Automated docking was used to assess the binding modes and 
conformation of the ligand molecules. Docking studies was 
performed for all the benzimidazopyrimidine and coumarin 
substituted benzimidazopyridimine derivatives. In docking 
study, all the compounds were found to have minimum 
binding energy ranging from -6.26 to -9.29 kJ/mol. Among the 
docked molecules, 2h, 2i, 2j and 2k revealed minimum binding 
energy of -8.8, -9.1, -8.9 and -9.29 kJ/mol, with ligand efficiency 
of -0.29, -0.29, -0.3 and -0.31, respectively. These molecules were 
completely wrapped by active site amino acid residues at the 
active site pocket region (as shown in Figure 3). 
 
The protein (3FDN) comprises of fifteen active site residues, 
which are promiscuous to the ligands. Out of which only two 
(Ala 213 and Asn 261) residues are directly interacting with the 
ligands. Most of the residues that are in close proximity to the 
inhibitor are hydrophobic in nature. All the ligands were 
docked deeply within the binding pocket region of 3FDN. The 
ligand molecules 2e, 2f, 2h and 2k were found to show 
hydrogen bond interaction with active site amino acid residues 
Ala 213 and Asn 261 at a distance of (1.923 and 2.203), (1.909 
and 1.925), (2.234 and 1.928) and (2.024 and 2.104) Å, 
respectively (Figure 4). The ligands 2a, 2b, 2g and 2j showed 
only one hydrogen bond interaction with protein, where as 
ligand 2c and 2i has no interaction with the protein. The 
docking results for all ligand molecules against protein target 
showed minimum intermolecular energy, ligand efficiency, 
binding energy, inhibition constant and vdW + Hbond + desolv 
energy with best RMSD value. From this study, we have 
predicted ligands 2h, 2i, 2j and 2k may act as potential 
inhibitors of human Aurora A kinase enzyme. 
 
 
Figure 4: H-bond interaction of ligand molecules (2e, 2f, 2h and 
2k) with 3FDN 
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Supplementary material: 
 
Table 1: Different groups of benzimidazopyrimidine and coumarin substituted benzimidazopyrimidine derivatives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: The dock score results of the different benzimidazopyrimidine and coumarin substituted benzimidazopyridimine 
derivatives 
Compounds Binding 
Energy 
(kJ mol-1) 
Ligand 
Efficiency 
Inhibition 
Constant 
vdW+H-
bond+desolv 
energy 
No. of 
H- 
bonds 
Bonding residues Bond 
Length 
 (Å) 
2a -6.26 -0.37 25.94 -6.55 1 3FDN:A:ALA213:HN 1.778 
2b -7.3 -0.3 4.47 -7.59 1 3FDN:A:ALA213:HN 1.959 
2c -7.28 -0.35 4.58 -7.48 - - - 
2d -8.03 -0.25 1.3 -9.23 2 3FDN:A:ALA213:HN 
3FDN:A:ASN261:HD22 
2.063 
2.064 
2e -8.13 -0.26 1.1 -8.89 2 3FDN:A:ALA213:HN 
3FDN:A:ASN261:HD22 
1.923 
2.203 
2f -8.39 -0.27 706.74 -9.33 2 3FDN:A:ALA213:HN 
3FDN:A:ASN261:HD22 
1.909 
1.925 
2g -8.67 -0.27 412.37 -9.49 1 3FDN:A:ALA213:HN 1.938 
2h -8.8 -0.29 354.57 -9.69 2 3FDN:A:ALA213:HN 
3FDN:A:ASN261:HD22 
2.234 
1.928 
2i -9.1 -0.29 214.1 -10.34 - - - 
2j -8.9 -0.3 301.24 -9.79 1 3FDN:A:ALA213:HN 2.18 
2k -9.29 -0.31 
 
155.7 -10.23 2 3FDN:A:ALA213:HN 
3FDN:A:ASN261:HD22 
2.024 
2.104 
 
Compounds R R1 
2a ipr - 
2b 4-CF3C6H4 - 
2c 3-FC6H4 - 
2d CF3 6- OCH3 
2e CF3 6-F 
2f CF3 6-CH3 
2g CF3 6,8-( OCH3)2 
2h ipr 6-F 
2i ipr 6-OCH3 
2j ipr 6-Cl 
2k ipr 6-Br 
